(NU/1433-22) ESP (Extracellular Synucleinopathic Protein) Diagnostics Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation
What the buyer wrote
Every year in the UK, around 20,000 new cases of Parkinson’s disease are diagnosed along with over 20,000 new cases of Dementia with Lewy bodies (DLB), the second commonest form of dementia after Alzheimer’s disease. Dementia is the biggest healthcare challenge globally, this being recognised in the UK through the Prime Minister’s Challenge on Dementia 2020 and the NHS England Five Year Forward View, where improving diagnosis, treatment and care is a core focus. These neurodegenerative disorders carry a huge economic burden, in the US alone the annual costs exceed $850 billion, with this estimated to double in the next three decades. DLB is the costliest type of dementia, with patients needi…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- (NU/1433-22) ESP (Extracellular Synucleinopathic Protein) Diagnostics Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Dynamic market
- Yes: you can apply to join at any time. How these work
- Where
- in the North East
- Kind of work
- Professional services, Clinical and healthcare services
Who the buyer named
Natalie Morton was the named contact on this notice.